Comparative Pharmacology
Head-to-head clinical analysis: VIGABATRIN versus XCOPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIGABATRIN versus XCOPRI.
VIGABATRIN vs XCOPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits GABA transaminase, increasing brain GABA levels.
XCOPRI (cenobamate) is a tetrazole derivative anticonvulsant that reduces neuronal excitability through inhibition of voltage-gated sodium channels (persistent sodium current) and positive allosteric modulation of GABA-A receptors.
Adults: 500 mg orally twice daily; may increase by 500 mg/day every 7 days up to 1500 mg twice daily. For refractory complex partial seizures, maximum 3000 mg/day.
Oral, 100 mg once daily for 2 weeks, then increase to 200 mg once daily. Maximum dose 400 mg once daily.
None Documented
None Documented
5-8 hours in young adults; 12-17 hours in elderly; prolonged with renal impairment.
Clinical Note
moderateVigabatrin + Venlafaxine
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine."
Clinical Note
moderateVigabatrin + Nefazodone
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone."
Clinical Note
moderateVigabatrin + Stiripentol
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Stiripentol."
Clinical Note
moderateVigabatrin + Clomipramine
50-70 hours, allowing once-daily dosing. Steady-state is reached in approximately 2 weeks.
Renal: ~80% unchanged in urine; fecal: <5%.
Primarily renal, with approximately 70% of the dose excreted as unchanged drug in urine and 30% as inactive metabolites. Fecal elimination accounts for <2%.
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine."